Plain-English translation of NCT07348601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help people with Prader-Willi Syndrome. Researchers want to understand whether the medication is safe, how well the body tolerates it, and whether it actually improves symptoms. The study will gradually increase the dose for each participant to find the right amount that works best.
Prader-Willi Syndrome causes serious behavioral and metabolic challenges that are difficult to manage with current treatments. This medication represents a new approach that researchers hope may help address these core problems.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic or participate via telemedicine for regular appointments where you'll take the medication at gradually increasing doses. Blood tests will be done to measure how much medication is in your system and to monitor your health. Your caregiver will need to be present during visits and will complete assessments about your behavior and wellbeing throughout the study. The study involves close monitoring to make sure the medication is working safely for you.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
ConSynance Therapeutics
Enrollment target
~12 participants
Started
May 2026
Primary completion
June 2027
Age range
13 Years – 50 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Beth Mack
ConSynance Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.